<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:23:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5505170" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5505170</identifier>
        <datestamp>2017-07-20</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>American Society of Clinical Oncology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5505170</article-id>
              <article-id pub-id-type="pmcid">PMC5505170</article-id>
              <article-id pub-id-type="pmc-uid">5505170</article-id>
              <article-id pub-id-type="pmid">27432915</article-id>
              <article-id pub-id-type="pmid">27432915</article-id>
              <article-id pub-id-type="publisher-id">660001</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.2015.66.0001</article-id>
              <article-categories>
                <subj-group subj-group-type="subjects">
                  <compound-subject>
                    <compound-subject-part content-type="code">GUC35</compound-subject-part>
                    <compound-subject-part content-type="label">Translational Oncology</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">PEDI14</compound-subject-part>
                    <compound-subject-part content-type="label">Renal Tumors</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">PEDI25</compound-subject-part>
                    <compound-subject-part content-type="label">Wilms' Tumor: Therapy</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">TO2</compound-subject-part>
                    <compound-subject-part content-type="label">Cancer Biomarkers</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">TO3</compound-subject-part>
                    <compound-subject-part content-type="label">Chromosomal Abnormalities</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">TO16</compound-subject-part>
                    <compound-subject-part content-type="label">Genitourinary</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">TO26</compound-subject-part>
                    <compound-subject-part content-type="label">Pediatric</compound-subject-part>
                  </compound-subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Pediatric Oncology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study</article-title>
                <alt-title alt-title-type="short">Gain of 1q As a Prognostic Biomarker in Wilms Tumors</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chagtai</surname>
                    <given-names>Tasnim</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zill</surname>
                    <given-names>Christina</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dainese</surname>
                    <given-names>Linda</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wegert</surname>
                    <given-names>Jenny</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Savola</surname>
                    <given-names>Suvi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Popov</surname>
                    <given-names>Sergey</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mifsud</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vujanić</surname>
                    <given-names>Gordan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sebire</surname>
                    <given-names>Neil</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Le Bouc</surname>
                    <given-names>Yves</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ambros</surname>
                    <given-names>Peter F.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kager</surname>
                    <given-names>Leo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O'Sullivan</surname>
                    <given-names>Maureen J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blaise</surname>
                    <given-names>Annick</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bergeron</surname>
                    <given-names>Christophe</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mengelbier</surname>
                    <given-names>Linda Holmquist</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gisselsson</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kool</surname>
                    <given-names>Marcel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tytgat</surname>
                    <given-names>Godelieve A.M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>van den Heuvel-Eibrink</surname>
                    <given-names>Marry M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graf</surname>
                    <given-names>Norbert</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>van Tinteren</surname>
                    <given-names>Harm</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coulomb</surname>
                    <given-names>Aurore</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gessler</surname>
                    <given-names>Manfred</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams</surname>
                    <given-names>Richard Dafydd</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Pritchard-Jones</surname>
                    <given-names>Kathy</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <aff id="aff1">Tasnim Chagtai, William Mifsud, Neil Sebire, Richard Dafydd Williams, and Kathy Pritchard-Jones, University College London Institute of Child Health, London; Sergey Popov, University Hospital of Wales; Gordan Vujanić, Cardiff University School of Medicine, Cardiff, United Kingdom; Christina Zill, Jenny Wegert, and Manfred Gessler, Wuerzburg University, Wuerzburg; Marcel Kool, German Cancer Research Center, Heidelberg; Norbert Graf, Saarland University Hospital, Homburg, Germany; Linda Dainese, Yves Le Bouc, Annick Blaise, and Aurore Coulomb, Sorbonne Universités; Linda Dainese, Yves Le Bouc, and Aurore Coulomb, Assistance Publique Hôpitaux de Paris–Hôpital Armand Trousseau, Paris; Christophe Bergeron, Centre Léon Bérard, Lyon, France; Suvi Savola, MRC-Holland; Harm van Tinteren, Netherlands Cancer Institute, Amsterdam; Godelieve A.M. Tytgat and Marry M. van den Heuvel-Eibrink, Princess Maxima Center for Pediatric Oncology/Hematology, Utrecht, the Netherlands; Peter F. Ambros and Leo Kager, Children's Cancer Research Institute; Leo Kager, St Anna Children's Hospital, Vienna, Austria; Maureen J. O'Sullivan, Our Lady's Children's Hospital, Dublin, Ireland; and Linda Holmquist Mengelbier and David Gisselsson, Lund University, Lund, Sweden.</aff>
              </contrib-group>
              <author-notes>
                <fn id="afn1" fn-type="equal">
                  <p>C.Z. and L.D. contributed equally to this work.</p>
                </fn>
                <corresp id="cor1">Corresponding author: Kathy Pritchard-Jones, MD, UCL Institute of Child Health, Guilford St, London, WC1N 1EH, United Kingdom; e-mail: <email>k.pritchard-jones@ucl.ac.uk</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>9</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>7</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>18</day>
                <month>7</month>
                <year>2016</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>34</volume>
              <issue>26</issue>
              <fpage>3195</fpage>
              <lpage>3203</lpage>
              <permissions>
                <copyright-statement>© 2016 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2016</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>Licensed under the Creative Commons Attribution 4.0 License: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:type="simple" content-type="pdf" xlink:href="jco.2015.66.0001.pdf"/>
              <abstract>
                <sec>
                  <title>Purpose</title>
                  <p>Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series.</p>
                </sec>
                <sec>
                  <title>Materials and Methods</title>
                  <p>WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 68.5% to 82.0%) and 88.2% in patients without gain (95% CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain (95% CI, 92.1% to 96.7%). In univariable analysis, 1q gain was associated with poorer EFS (<italic>P</italic> &lt; .001; hazard ratio, 2.33) and OS (<italic>P</italic> = .01; hazard ratio, 2.16). The association of 1q gain with poorer EFS retained significance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aberrations associated with poorer EFS included <italic>MYCN</italic> gain and <italic>TP53</italic> loss.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <equation-count count="0"/>
                <ref-count count="32"/>
                <page-count count="11"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>DJS Export</meta-name>
                  <meta-value>v1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Wilms tumor (WT) is the most common childhood renal malignancy.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Most patients are treated effectively, with approximately 90% achieving 5-year survival, but new approaches are needed to improve the outcome of the remainder, especially in cases of recurrence, where only approximately 50% will survive.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup> More specific biomarkers for treatment stratification could also reduce the therapeutic burden on the successfully treated majority. Treatment planning is currently determined by clinical staging and histopathologic criteria. In countries that follow the protocols of the International Society of Paediatric Oncology (SIOP), patients with WT typically receive neoadjuvant chemotherapy, and the histopathology at nephrectomy is used to classify patients into risk groups. Tumors with diffuse anaplasia or that contain a high proportion of chemoresistant blastema (blastemal type) are regarded as high risk; epithelial, stromal, mixed, and regressive subtypes are classed as intermediate risk, and completely necrotic tumors are classed as low risk.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> Using this classification, the SIOP WT 2001 trial recently reported that doxorubicin can be safely omitted from the treatment of stage II to III intermediate-risk histology tumors, although it still adds benefit when patients have high-risk histology.<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> However, high-risk tumors are relatively uncommon, and most relapses still occur in patients with localized (stage I to III) low- and intermediate-risk histology tumors. Therefore, there is a clinical need to improve the sensitivity and specificity of risk prediction in WT. The SIOP WT 2001 trial included, as a secondary aim, investigation of the potential value of including molecular biomarkers in addition to the current use of tumor stage and histology in risk stratification.</p>
              <p>Previous analyses have identified multiple recurrent aberrations in WT. Notable genes with documented mutations include <italic>WT1</italic>,<sup><xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B9" ref-type="bibr">9</xref></sup>
<italic>CTNNB1</italic>,<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
<italic>WTX</italic> (<italic>AMER1</italic>),<sup><xref rid="B11" ref-type="bibr">11</xref></sup>
<italic>TP53</italic>,<sup><xref rid="B12" ref-type="bibr">12</xref></sup>
<italic>FBXW7</italic>,<sup><xref rid="B13" ref-type="bibr">13</xref></sup>
<italic>MYCN</italic>, <italic>SIX1/2</italic>, <italic>DICER1</italic>, <italic>DROSHA</italic>, and <italic>DGCR8</italic>.<sup><xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B18" ref-type="bibr">18</xref></sup> Copy neutral loss of heterozygosity on 11p, common in stromal-type tumors, can lead to both second hit inactivation of mutated <italic>WT1</italic> on 11p13 and aberrant expression of the imprinted genes <italic>H19</italic> and <italic>IGF2</italic> on 11p15; the latter locus is also frequently targeted by epigenetic abnormalities.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Several WT genes, including <italic>WT1</italic>, <italic>WTX</italic>, <italic>TP53</italic>, <italic>FBXW7</italic>, and <italic>MYCN</italic> are also subject to recurrent copy number aberrations, as are a number of larger-scale genomic regions, but few of these are of known prognostic relevance. Simultaneous allele loss of 1p and 16q is associated with adverse outcome in patients with favorable-histology WT treated with immediate nephrectomy, and this biomarker is already used in treatment stratification by the Children's Oncology Group of North America.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> We have recently shown that <italic>TP53</italic> mutation and 17p loss, aberrations largely confined to anaplastic histology WT, are potential adverse indicators within this subtype.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> However, the utility of both these biomarkers is limited by their relative rarity. Genomic gain of 1q, one of the most common copy number changes in WT,<sup><xref rid="B22" ref-type="bibr">22</xref>-<xref rid="B25" ref-type="bibr">25</xref></sup> seems to be associated with poor outcome, as is gain of <italic>MYCN</italic>.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> Recent studies in the United States and United Kingdom have focused on the significance of 1q gain and support its prognostic value.<sup><xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref></sup></p>
              <p>The principal aim of this study was to assess the feasibility of using 1q gain as a prognostic biomarker by determining its association with event-free survival (EFS) and overall survival (OS) in a cohort drawn entirely from the SIOP WT 2001 clinical trial (which is, to our knowledge, the largest SIOP cohort so far analyzed for this biomarker). Accordingly, a rapid and relatively low-cost multiplex ligation-dependent probe amplification (MLPA) assay<sup><xref rid="B28" ref-type="bibr">28</xref></sup> was developed and optimized to assess the copy number status of 1q and other key regions or gene-specific loci, including 1p, 16q, <italic>WT1</italic>, <italic>WTX</italic>, <italic>TP53</italic>, <italic>MYCN,</italic> and <italic>FBXW7</italic>.</p>
            </sec>
            <sec sec-type="materials|methods" id="s2">
              <title>MATERIALS AND METHODS</title>
              <sec id="s3">
                <title>Patients</title>
                <p>Patients registered prospectively in the SIOP WT 2001 clinical trial and treated with preoperative chemotherapy according to standardized risk-stratified regimens on the basis of tumor stage, histology, and metastatic response to preoperative chemotherapy<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B29" ref-type="bibr">29</xref></sup> with stage I to IV WT and available frozen tumor were eligible for this study. Selection criteria and patient characteristics are provided in the Data Supplement (Methods). Informed consent was obtained from all families. Our research was approved by local ethics committees and conducted in accordance with the Helsinki Declaration.</p>
              </sec>
              <sec id="s4">
                <title>Samples</title>
                <p>All samples were freshly frozen specimens obtained at nephrectomy. Genomic DNA was prepared by standard methods. Only WT with a tumor content ≥ 50% as determined by a pediatric pathologist were used for this study (N = 586; Data Supplement Table S1). Full details, including sample inclusion criteria and DNA quality control (QC) metrics, are listed in the Data Supplement.</p>
              </sec>
              <sec id="s5">
                <title>MLPA</title>
                <p>The MLPA assay (P380-X2) was designed and developed in collaboration with MRC-Holland (Amsterdam, the Netherlands). The panel included 33 probes for regions or genes of interest, including seven on 1p, five on 1q, six on 16q, and three each targeting <italic>MYCN</italic> (2p), <italic>TP53</italic> (17p), <italic>FBXW7</italic> (4q), <italic>WT1</italic> (11p), and <italic>WTX</italic> (<italic>AMER1</italic>, Xq), as well as reference and QC probes (Data Supplement Table S2). MLPA reactions were performed according to the manufacturer’s instructions, with appropriate internal quality and external normal controls. Polymerase chain reaction products were analyzed on an ABI 3730 DNA Analyzer, (Thermo Fisher Scientific, Waltham, MA).</p>
              </sec>
              <sec id="s6">
                <title>Data Analysis</title>
                <p>Copy number ratios relative to the normal reference were calculated with Coffalyser.NET software (MRC-Holland) using the default settings. A numerical gain was scored when the ratios exceeded 1.2 and a loss when the ratios were lower than 0.8; all other values were considered to be normal diploid. For individual genes, aberrations were scored by the median ratio of the gene-specific probes. For 1p, 1q, and 16q, a gain or loss of at least two consecutive probed loci was required to score a chromosome arm aberration. Associations between copy number aberrations and histopathologic subtypes (<xref ref-type="fig" rid="F1">Fig 1</xref>) were calculated by logistic regression, and survival analyses (<xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="fig" rid="F2">Fig 2</xref>; Data Supplement) were performed using the Kaplan-Meier estimator, log-rank test, and Cox proportional hazards regression model (Data Supplement Methods). For multivariable analyses, the factors considered are listed in the “Variable” column of <xref ref-type="table" rid="T2">Table 2</xref>.</p>
                <fig id="F1" fig-type="figure" orientation="portrait" position="float">
                  <label>Fig 1.</label>
                  <caption>
                    <p>Aberration frequency histograms for loci of interest in specific histologic subtypes of Wilms tumor (full series, N = 586). AH, anaplastic histology.</p>
                  </caption>
                  <graphic xlink:href="jco660001f1"/>
                </fig>
                <fig id="F2" fig-type="figure" orientation="portrait" position="float">
                  <label>Fig 2.</label>
                  <caption>
                    <p>(A, C, E) Event-free (EFS) and (B, D, F) overall survival (OS) curves for (A, B) complete series, (C, D) intermediate-risk localized disease, and (E, F) nonanaplastic localized disease Wilms tumors, stratified by 1q status. AH, anaplastic histology.</p>
                  </caption>
                  <graphic xlink:href="jco660001f2"/>
                </fig>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Univariable Survival Analyses</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="jco660001t1"/>
                    <table frame="hsides" rules="groups">
                      <col width="15.16%" span="1"/>
                      <col width="16.16%" span="1"/>
                      <col width="5.45%" span="1"/>
                      <col width="7.93%" span="1"/>
                      <col width="7.23%" span="1"/>
                      <col width="8.2%" span="1"/>
                      <col width="8.98%" span="1"/>
                      <col width="6.59%" span="1"/>
                      <col width="7.31%" span="1"/>
                      <col width="8.54%" span="1"/>
                      <col width="8.45%" span="1"/>
                      <thead>
                        <tr>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Patient Series</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Aberration</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of Patients</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of Relapses</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Event <italic>P</italic></th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Event HR</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">5-Year EFS</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of Deaths</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Death <italic>P</italic></th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Death HR</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">5-Year OS</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unselected patients</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">167</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">43</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.33</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">75</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">19</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.01</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.16</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">88.4</td>
                        </tr>
                        <tr>
                          <td rowspan="19" valign="top" align="left" scope="row" colspan="1">(N = 586)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">419</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">49</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">88.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">22</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">94.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">49</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.17</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.55</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">77.9</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.38</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.52</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">89</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">537</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">81</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">85</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">36</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">93</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">94</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">20</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.12</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.48</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">78.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.07</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.88</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">89.1</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">492</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">72</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">85.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">30</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">93.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">16</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.76</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.22</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">81.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.27</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">570</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">89</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">84.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">41</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">92.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">44</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">19</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">4.03</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">55.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">16</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">9.80</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">63.7</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">542</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">73</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">86.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">25</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">94.9</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">50</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.45</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.73</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">86.6</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.15</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.26</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">97.8</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">536</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">86</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">84.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">40</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">92.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">93</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.13</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.61</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">91.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.04</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.26</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">97.8</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">493</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">82</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">83</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">39</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">91.6</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">88</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">26</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">71.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.09</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">83.7</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">498</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">66</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">86.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">27</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">94.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">60</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">20</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.72</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">67.9</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">12</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.91</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">79.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">526</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">72</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">86.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">29</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">94.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">24</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">15</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">6.58</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">38</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">9.62</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">59.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">562</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">77</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">86.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">31</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">94</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">IR stage I-III</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">114</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">22</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.004</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.21</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">82.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.99</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">98</td>
                        </tr>
                        <tr>
                          <td rowspan="19" valign="top" align="left" scope="row" colspan="1">(n = 441)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">327</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">29</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">91.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">34</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.27</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.61</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">83.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.88</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.17</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">97</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">407</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.5</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">59</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">9</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.4</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.36</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">84.6</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.21</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">96.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">382</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">42</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.6</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.69</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.33</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">84.6</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.56</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">428</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">49</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">89</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">19</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.004</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.23</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">67.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">8.33</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">88.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">422</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.9</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.8</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">42</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.94</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.03</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">86.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.29</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.00</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">399</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">46</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">79</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.58</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.81</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">92.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.11</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.00</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">362</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">43</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">88.1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">96.9</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">61</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.003</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.49</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">78.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.03</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.50</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">93.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">380</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">37</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">90.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">7</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">98.1</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">42</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.86</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">75.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.002</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">5.49</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">90.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">399</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">40</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">90.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">7</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">98.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">4.85</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">59.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.23</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.25</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">428</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.9</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.4</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-AH stage I-III</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">131</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">26</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.34</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">81.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.48</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">95.7</td>
                        </tr>
                        <tr>
                          <td rowspan="19" valign="top" align="left" scope="row" colspan="1">(n = 482)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">351</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">30</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">91.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">98.1</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">42</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.13</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.78</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">82</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.05</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.47</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">92.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">440</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">48</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">9</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.9</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">64</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">9</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.59</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.22</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">85.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.8</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.22</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">98.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">418</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">47</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">89</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.2</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.76</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">1.25</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">85.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.55</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1p and 16q other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">468</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">54</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">88.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">12</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">17</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.02</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.82</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">69.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.02</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">5.24</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">93.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>TP53</italic> (17p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">465</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">51</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.5</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.9</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.94</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">87.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.27</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.00</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WT1</italic> (11p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">437</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">51</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">88.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">12</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.1</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">81</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.5</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.77</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">92.6</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">0.00</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>WTX</italic> (Xq) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">401</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">48</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">87.7</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">12</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">96.8</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">63</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.01</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.30</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">78.9</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.04</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.23</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">93.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (2p) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">419</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">42</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">90.1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">98</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">43</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.002</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">2.68</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">76.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.003</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">5.10</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">90.3</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>MYCN</italic> (only) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">439</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.8</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">98.1</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">&lt; .001</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">4.83</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">59.3</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">.23</td>
                          <td rowspan="2" valign="top" align="center" colspan="1">3.28</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1"><italic>FBXW7</italic> (4q) other</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">469</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">50</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">89.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">11</td>
                          <td valign="top" colspan="1" align="center" rowspan="1">97.3</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="abbr">
                      <p>Abbreviations: AH, anaplastic histology; EFS, event-free survival; HR, hazard ratio; IR, intermediate risk; OS, overall survival.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Multivariable Survival Analyses</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="jco660001t2"/>
                    <table frame="hsides" rules="groups">
                      <col width="15.26%" span="1"/>
                      <col width="7.98%" span="1"/>
                      <col width="13.48%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <col width="7.91%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Patient Series</th>
                          <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Variable</th>
                          <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Comparison</th>
                          <th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1">Event-Free Survival</th>
                          <th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1">Overall Survival</th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">
                            <italic>P</italic>
                          </th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">HR</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Lower</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Upper</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">
                            <italic>P</italic>
                          </th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">HR</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Lower</th>
                          <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Upper</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="9" valign="top" align="left" scope="row" colspan="1">Unselected patients (n = 585)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1p loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.95</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.98</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.91</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.67</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.24</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.89</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1q gain</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.002</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.98</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.07</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.16</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.61</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.83</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.15</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.63</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.14</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.68</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.91</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.39</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.37</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.67</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.83</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Female</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.98</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.99</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.65</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.51</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.81</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.93</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.49</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.74</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage II</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.43</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.71</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.96</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">10.26</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage III</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.17</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.52</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.83</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.79</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4.39</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.36</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14.12</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage IV</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">&lt; .001</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4.58</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.58</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8.15</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">&lt; .001</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">21.65</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6.93</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">67.66</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">High risk</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Intermediate risk</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.001</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.28</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.41</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.68</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">&lt; .001</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">8.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">4.05</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">16.32</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Age</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Per unit</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.48</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.99</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                        </tr>
                        <tr>
                          <td rowspan="7" valign="top" align="left" scope="row" colspan="1">IR stage I-III (n = 440)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1p loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.97</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.02</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.41</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.84</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.81</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6.74</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1q gain</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.04</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.92</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.05</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.51</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.44</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.56</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.42</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.64</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.56</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.55</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.09</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.51</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.82</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">15.12</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Female</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.73</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.41</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.28</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.04</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.24</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.92</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage II</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.76</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.11</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.57</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.18</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.25</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.71</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">14.82</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage III</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.73</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.85</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.54</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.02</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">7.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">33.78</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Age</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Per unit</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.32</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.71</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.99</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.02</td>
                        </tr>
                        <tr>
                          <td rowspan="8" valign="top" align="left" scope="row" colspan="1">Non-AH stage I-III (n = 481)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1p loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.73</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.15</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.52</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.54</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.75</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">7.61</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">1q gain</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No gain</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.02</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.13</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.57</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.62</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.39</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.38</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5.11</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">16q loss</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">No loss</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.96</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.98</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.46</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.77</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.27</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.26</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">6.29</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Female</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Male</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.33</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.77</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.31</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.04</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.24</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.93</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage II</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.36</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.34</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.72</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">2.5</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.05</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5.12</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.99</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">26.4</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Stage III</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Stage I</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.26</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.51</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.74</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">3.08</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.06</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">5.58</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.91</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">34.08</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">High risk</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Intermediate risk</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.71</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.85</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.38</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.94</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.45</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.71</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.42</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">7</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">Age</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">Per unit</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.11</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">.53</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.01</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">0.99</td>
                          <td valign="top" align="center" rowspan="1" colspan="1">1.02</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="abbr">
                      <p>Abbreviations: AH, anaplastic histology; HR, hazard ratio; IR, intermediate risk.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="results" id="s7">
              <title>RESULTS</title>
              <sec id="s8">
                <title>Sample Series and Histologic Subtypes</title>
                <p>A total of 586 patients with stages I to IV WTs, in which tumor content was confirmed by histologic review, high-quality DNA was successfully extracted, and data exceeded QC thresholds (Data Supplement Methods), were included in the analysis. In this series (Data Supplement Table S1), median clinical follow-up was 68 months, 92 patients had an event (relapse), and 41 patients died. In 55% of tumors (321 of 586), at least one of the major copy number aberrations targeted by the assay (1q gain, 1p loss, 16q loss, <italic>MYCN</italic> gain, <italic>TP53</italic> loss, <italic>WT1</italic> loss, <italic>WTX</italic> loss, or <italic>FBXW7</italic> loss) was detected (Data Supplement Table S1). Overall, the numbers of alterations identified across all markers were consistent with previous reports. Some aberrations were more common in specific subtypes (<xref ref-type="fig" rid="F1">Fig 1</xref>; Data Supplement Table S3) and some significant associations were noted. Compared with mixed-type histology, diffuse anaplasia was significantly associated with <italic>TP53</italic> (17p) loss (<italic>P</italic> &lt; .001), <italic>MYCN</italic> (2p) gain (<italic>P</italic> &lt; .001), 16q loss (<italic>P</italic> &lt; .001), and <italic>FBXW7</italic> (4q) loss (<italic>P</italic> &lt; .001), the latter presumably reflecting an association between anaplasia and whole-arm 4q loss, which we have described previously.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> The stromal subtype was associated with <italic>WT1</italic> (11p) loss (<italic>P</italic> = .0014), consistent with previous reports, and with a significantly lower frequency of 1q gain than the other subtypes (<italic>P</italic> = .00912). A gain of 1q was most frequent in blastemal-type tumors (<xref ref-type="fig" rid="F1">Fig 1</xref>), but not to a statistically significant extent. We also noted an association between the regressive type and a lower frequency of <italic>WTX</italic> (<italic>AMER1</italic>, Xq) loss. Most aberrations, including 1q gain, were somewhat less common in stage I than in higher stage tumors (Data Supplement Table S4).</p>
              </sec>
              <sec id="s9">
                <title>Univariable Outcome Analysis of 1q Gain</title>
                <p>In the complete series of 586 patients (<xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="fig" rid="F2">Figs 2A and 2B</xref>), 167 tumors (28.5%) had 1q gain. Five-year EFS in the 1q-gain group was 75.0% (95% CI, 68.5% to 82.0%) and 88.2% in the no-gain group (95% CI, 85.0% to 91.4%). The corresponding OS values were 88.4% (95% CI, 83.5% to 93.6%) and 94.4% (95% CI, 92.1% to 96.7%), respectively. At the alpha significance level of .05, univariable analyses using the Cox proportional hazards regression model showed that 1q gain was associated with poorer EFS (hazard ratio [HR], 2.33; log-rank <italic>P</italic> &lt; .001) and OS (HR, 2.16; <italic>P</italic> = .01).</p>
                <p>Because 1q gain as a potential biomarker would be of most value in optimizing risk stratification in localized tumors, we also considered two important subsets. The first consisted of 441 patients with localized disease (stage I to III), intermediate-risk histology tumors according to the SIOP classification. In univariable analysis (<xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="fig" rid="F2">Figs 2C and 2D</xref>), 1q gain was significantly associated with inferior EFS (<italic>P</italic> = .004; HR, 2.21) but not OS (<italic>P</italic> = .99; HR, 1.01). The second subset was selected to allow direct comparison with the Children’s Oncology Group risk stratification. Among 482 patients with localized, nonanaplastic tumors (ie, excluding both diffuse and focal anaplastic but including blastemal-type WTs), 1q gain was associated with poorer EFS (<italic>P</italic> = .001; HR, 2.34) but not OS (<italic>P</italic> = .1; HR, 2.48; <xref ref-type="table" rid="T1">Table 1</xref>; <xref ref-type="fig" rid="F2">Figs 2E and 2F</xref>).</p>
              </sec>
              <sec id="s10">
                <title>Univariable Outcome Analysis of 1p Loss and 16q Loss</title>
                <p>Neither 1p loss nor 16q loss, nor combined loss of 1p and 16q, considered as a single biomarker in a univariable Cox model, was significantly associated with EFS or OS in the entire tumor series at the <italic>P</italic> = .05 level (Data Supplement). This was also true for the subsets, with the single exception of a marginal association between 1p loss and poorer OS in nonanaplastic patients (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Figs S1, S2, and S3).</p>
              </sec>
              <sec id="s11">
                <title>Multivariable Outcome Analyses</title>
                <p>In a multivariable outcome analysis including 1q gain, 1p loss, 16q loss, tumor stage and histologic risk group, sex, and age, 1q gain was significantly associated with poorer EFS (HR, 1.98; <italic>P</italic> = .002), but not OS (HR, 1.61; <italic>P</italic> = .16; <xref ref-type="table" rid="T2">Table 2</xref>). The only other independent factors of those assessed for adverse outcome in the full series (N = 586) were high-risk histology and stage IV disease. The significant independent association of 1q gain with adverse EFS but not OS persisted in the subsets of intermediate-risk histology, localized WT (n = 440; EFS HR, 1.92; <italic>P</italic> = .04) and nonanaplastic, localized WT (n = 481; EFS HR, 2.0; <italic>P</italic> = .02).</p>
              </sec>
              <sec id="s12">
                <title>Univariable Analysis of Gene-Specific Markers</title>
                <p>The outcome data for the other markers covered by the assay were also analyzed on an exploratory basis (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Figs S4-S9). <italic>MYCN</italic> (2p) gain was significantly associated with poorer EFS and OS in the complete data set, in the localized disease intermediate-risk subset, and in the localized disease subset with anaplastic WTs excluded (Data Supplement Fig S4). Using a more specific definition of <italic>MYCN</italic> gain, <italic>MYCN</italic>-only gain (excluding from the <italic>MYCN</italic>-gain group those tumors in which the <italic>DYSF</italic> control probe on 2p was also gained, because gains at both loci were likely to be whole-arm gains), we saw higher HRs and lower <italic>P</italic> values (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Fig S5). Similarly, <italic>TP53</italic> (17p) loss was significantly associated with inferior EFS and OS in the complete series and, perhaps surprisingly, in both subsets, neither of which included diffuse anaplastic WTs (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Fig S6).</p>
                <p>A third copy number change, loss of the <italic>FBXW7</italic> locus on 4q, was significantly associated with poorer EFS and OS in the complete 586 tumor series, but only with poorer EFS in both subsets (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Fig S7). No significant associations were noted between the copy number status of <italic>WT1</italic> and outcome at the <italic>P</italic> = .05 significance level (<xref ref-type="table" rid="T1">Table 1</xref>; Data Supplement Fig S8). For <italic>WTX</italic>, there was no significant association with EFS, but improved OS was marginally associated with copy number loss in the complete series only (<italic>P</italic> = .04; Data Supplement Fig S9).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s13">
              <title>DISCUSSION</title>
              <p>This is, to our knowledge, the first study to carry out a large-scale analysis of 1q copy number aberrations in WT sampled at nephrectomy after neoadjuvant chemotherapy according to the SIOP WT 2001 protocol. The clinical characteristics of the patient cohort were representative of the entire registered population who had received preoperative chemotherapy and presented with unilateral disease; 586 patients with stage I to IV WT, including all intermediate- and high-risk histologic subtypes, were analyzed. We found that 1q gain is significantly associated with poorer EFS and OS in univariable analyses, with HRs in excess of two-fold for relapse and death. These results are broadly consistent with those recently reported in a study of patients treated by immediate nephrectomy under Children's Oncology Group protocols without preoperative chemotherapy<sup><xref rid="B26" ref-type="bibr">26</xref></sup> and, although it is essential to assess 1q gain independently in cohorts treated under both regimens, it is encouraging to note that it seems to be a prognostically valuable marker regardless of treatment protocol. However, in our multivariable analysis of the SIOP data, which also considered 1p loss, 16q loss, sex, stage, age, and histologic risk group, 1q gain remained significantly associated only with EFS (HR, 1.98; <italic>P</italic> = .002) and not OS (HR, 1.61; <italic>P</italic> = .16). This lack of association with OS is perhaps not surprising, given the comparatively low number of deaths in the patient series (41, compared with 92 relapses), reflecting the relative success of second-line therapy.</p>
              <p>Because just over half of all relapses occur in children with localized WT that are not of high-risk histology, we analyzed this subset of patients (n = 441) in which treatment intensification to reduce relapse risk would be clinically appropriate and feasible. Here, we found that 1q gain retained its independent prognostic significance for EFS (HR, 1.92; <italic>P</italic> = .04) but not OS in multivariable analysis. Similar results (HR, 2.00; <italic>P</italic> = .02) were obtained for localized nonanaplastic tumors (n = 481), excluding both diffuse and focal anaplastic WTs but retaining blastemal type. This subset is comparable to the current North American definition of favorable histology for localized patients treated by immediate nephrectomy (where blastemal type, which implies chemoresistance, cannot be defined).</p>
              <p>In contrast to a previous report on immediate nephrectomy patients,<sup><xref rid="B20" ref-type="bibr">20</xref></sup> we did not find that the combination of 1p loss and 16q loss was prognostically significant in the SIOP series in the univariable or multivariable analyses. This was true for both EFS and OS, in the entire series, and in the nonanaplastic and intermediate-risk subsets. However, the size of our sample series (significantly smaller than the immediate nephrectomy cohort) meant that the current study did not have sufficient power to assess reliably the prognostic significance of relatively rare aberrations such as combined 1p and 16q loss, observed in only 16 patients (three of whom relapsed). We note also that any copy neutral loss of heterozygosity, another possible mechanism of allele loss at these loci, would not be detected by MLPA. A substantially larger series would be required to obtain definitive results for this rare combined marker in SIOP patients.</p>
              <p>In a previous study,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> we presented an analysis of <italic>MYCN</italic> copy number status that included 234 of the samples described in this study. Therefore, our observations are not independent, but the current expanded series should give a more reliable indication of the prognostic relevance of <italic>MYCN</italic> gain. As before, we note that <italic>MYCN</italic> gain seems to be a promising adverse prognostic indicator for WT, for both EFS and OS (Data Supplement Fig S4). We also analyzed the data using a more specific definition of gain (<italic>MYCN</italic>-only gain; Data Supplement Fig S5), excluding whole-arm gains. The adverse association with both EFS and OS was retained in all univariable analyses, but with lower <italic>P</italic> values and higher HRs throughout, perhaps suggesting that the type of genomic disruption that has given rise to <italic>MYCN</italic> gain, rather than the relative dose of <italic>MYCN</italic> with regard to the genomic baseline, is more prognostically relevant. A higher resolution (eg, single nucleotide polymorphism array) platform that allows precise delineation of the region of gain and distinguishes between focal events, such as those we described previously,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> and larger segmental changes would allow us to address this question.</p>
              <p>In a previous study we described an association between poor outcome and <italic>TP53</italic> aberrations (typically point mutation coincident with whole-arm copy number loss of 17p) in diffuse anaplastic tumors.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> Interestingly, <italic>TP53</italic> (17p) loss in the current study was associated with poorer EFS and OS, even in the subsets that excluded anaplastic tumors. It is currently not known whether the nonanaplastic tumors with copy number loss at this locus also had <italic>TP53</italic> mutations or whether these tumors had any unusual histologic features, such as nuclear unrest.<sup><xref rid="B31" ref-type="bibr">31</xref></sup></p>
              <p>Loss of the <italic>FBXW7</italic> locus on 4q was significantly associated with poorer EFS and OS in the complete tumor series and with adverse EFS only in the subsets. In earlier studies, we reported focal homozygous loss and point mutation of <italic>FBXW7</italic> in several intermediate-risk histology WTs,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> as well as broader but typically single copy loss of 4q associated with anaplasia<sup><xref rid="B30" ref-type="bibr">30</xref></sup>; the current assay does not distinguish between these types of aberrations.</p>
              <p>Optimizing treatment to minimize the risk of long-term adverse effects without compromising EFS or OS is a principal aim of clinical research in WT. The previous SIOP randomized trial<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> showed that therapeutic intensity could be reduced in patients with localized intermediate-risk tumors without affecting OS, at the cost of a 4.4% reduction in EFS (95% CI, 0.4% to 9.3%). Because it is clearly desirable for patients to avoid even treatable relapses, further refinement of first-line therapy remains a priority, and novel biomarkers may provide the key data required to improve risk stratification and maximize EFS. In this study, we have shown that MLPA provides a rapid and effective means of determining the status of copy number aberrations associated with poorer EFS. The relatively high frequency of 1q gain makes this marker particularly attractive for potential use in risk stratification. However, any change in intensity on the basis of 1q status alone would affect a significant proportion of patients who have experienced a reasonably good EFS when treated with current therapies and where relapse is salvageable. Hence, the SIOP Renal Tumours Study Group considers it may be more appropriate to define risk groups for treatment stratification on the basis of several combined molecular biomarkers, taking account of our findings of the adverse significance of <italic>MYCN</italic> gain and <italic>TP53</italic> loss and incorporating mutations in recently discovered WT genes, some of which are reported to have prognostic significance. This requires a prospective clinical study powered to include tumor stage and histologic risk group, both individually significant in our multivariable analysis, alongside quantitative assessment of the volume of blastema that survives preoperative chemotherapy, a further potential prognostic factor.<sup><xref rid="B32" ref-type="bibr">32</xref></sup> This prospective study will also incorporate multiple sampling of each WT to determine the extent of intratumoral heterogeneity of 1q gain and other biomarkers. It will register all patients with a newly diagnosed renal tumor and continue the risk stratification and treatment arms for localized WT used in the SIOP WT 2001 trial. The study will be known as UMBRELLA, and is expected to open in 2016.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn id="fn0" fn-type="other">
                <p>Listen to the podcast by Dr Geoerger at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org/podcasts">www.jco.org/podcasts</ext-link></p>
              </fn>
              <fn id="fn1" fn-type="other">
                <p>Written on behalf of the International Society of Paediatric Oncology Renal Tumours Study Group.</p>
              </fn>
              <fn id="fn2" fn-type="supported-by">
                <p>Supported in the United Kingdom by Cancer Research UK (Grant No. C1188/A4614), Great Ormond Street Hospital (GOSH) Children's Charity, Children with Cancer (Grant No. 11MH16), and the National Institute for Health Research GOSH University College London Biomedical Research Centre; in Germany by the Deutsche Forschungsgemeinschaft (Grant No. Ge539/12-1), the Wilhelm-Sander-Stiftung, and the Competence Network Paediatric Oncology and Haematology; in France by L'Association Léon Bérard pour les Enfants Cancéreux, Enfants et Santé, Société Française du Cancer de l'Enfant, Institut National de la Santé et de la Recherche Médicale and Université Pierre et Marie Curie (Grant No. UMR.S 938); in Austria by a clinical investigator–driven grant of the St Anna Kinderkrebsforschung (P.F.A. and L.K.); and in multiple countries by the European Network for Cancer Research in Children and Adolescents (EU FP7 Grant No. 261474) and the P-medicine Project (EU FP7 Grant No. 270089).</p>
              </fn>
              <fn id="fn3" fn-type="COI-statement">
                <p>Authors’ disclosures of potential conflicts of interest are found in the article online at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>. Author contributions are found at the end of this article.</p>
              </fn>
              <fn id="fn4" fn-type="other">
                <p>Clinical trial information: 2007-004591-39.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgment</title>
              <p>We thank all the families who donated samples and all the staff at the treatment centers in the United Kingdom, Republic of Ireland, Germany, Austria, France, the Netherlands, and Sweden who enrolled patients in the SIOP WT 2001 trial and study and collected frozen tumor for the biologic studies. This study builds on the work of Jan de Kraker, MD, original chief investigator of the SIOP WT 2001 trial, who died on January 19, 2012. We thank Rebecca West and Nelly Bier for technical assistance, and Mariana Maschietto for helpful comments during the development of this study. The United Kingdom clinical database was managed by the Children's Cancer Trials Team, Cancer Research UK Clinical Trials Unit, Birmingham. Samples were made available by individual treatment centers, in the United Kingdom by the Children's Cancer and Leukaemia Group, and in France by the French Pediatric Renal Tumor Pathology Group, Cardiobiotec, Tumorothèque Marseille, Service de Pathologie Robert-Debré Assistance Publique Hôpitaux de Paris–Université Denis-Diderot Paris 7–Sorbonne Paris Cité, Tumorothèque Necker–Enfants malades, Centre de Ressources Biologiques (CRB) Paris Sud, Tumorothèque Champagne-Ardenne, Tumorothèque Caen Basse-Normandie, Tumorothèque Régionale Franche Comté, CRB Grenoble, Tumorothèque Lille–Centre Régional de Référence en Cancérologie, Tumorothèque du Limousin, and CRB Hôpitaux Universitaires de Strasbourg.</p>
            </ack>
            <sec id="s15">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Tasnim Chagtai, Suvi Savola, Gordan Vujanić, David Gisselsson, Marry M. van den Heuvel-Eibrink, Norbert Graf, Harm van Tinteren, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones</p>
              <p><bold>Collection and assembly of data:</bold> All authors</p>
              <p><bold>Data analysis and interpretation:</bold> Tasnim Chagtai, Christina Zill, Linda Dainese, Jenny Wegert, Gordan Vujanić, Yves Le Bouc, Peter F. Ambros, Annick Blaise, Marry M. van den Heuvel-Eibrink, Harm van Tinteren, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
            </sec>
            <sec id="s16">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec id="s17">
                <title>Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://jco.ascopubs.org/site/ifc">jco.ascopubs.org/site/ifc</ext-link>.</p>
              </sec>
              <sec id="s18">
                <title>Tasnim Chagtai</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s19">
                <title>Christina Zill</title>
                <p><bold>Employment:</bold> Roche Diagnostics Deutschland</p>
                <p><bold>Honoraria:</bold> Roche Diagnostics Deutschland</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Roche Diagnostics Deutschland</p>
              </sec>
              <sec id="s20">
                <title>Linda Dainese</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s21">
                <title>Jenny Wegert</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s22">
                <title>Suvi Savola</title>
                <p><bold>Employment:</bold> MRC-Holland</p>
              </sec>
              <sec id="s23">
                <title>Sergey Popov</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s24">
                <title>William Mifsud</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s25">
                <title>Gordan Vujanić</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s26">
                <title>Neil Sebire</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s27">
                <title>Yves Le Bouc</title>
                <p><bold>Honoraria:</bold> Ipsen, Sandoz</p>
                <p><bold>Consulting or Advisory Role:</bold> Sandoz</p>
                <p><bold>Speakers' Bureau:</bold> Ipsen</p>
                <p><bold>Research Funding:</bold> Sandoz (Inst)</p>
              </sec>
              <sec id="s28">
                <title>Peter F. Ambros</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s29">
                <title>Leo Kager</title>
                <p><bold>Travel, Accommodations, Expenses:</bold> Novartis</p>
              </sec>
              <sec id="s30">
                <title>Maureen J. O'Sullivan</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s31">
                <title>Annick Blaise</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s32">
                <title>Christophe Bergeron</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s33">
                <title>Linda Holmquist Mengelbier</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s34">
                <title>David Gisselsson</title>
                <p><bold>Consulting or Advisory Role:</bold> Spago Nanomedical</p>
              </sec>
              <sec id="s35">
                <title>Marcel Kool</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s36">
                <title>Godelieve A.M. Tytgat</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s37">
                <title>Marry M. van den Heuvel-Eibrink</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s38">
                <title>Norbert Graf</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s39">
                <title>Harm van Tinteren</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s40">
                <title>Aurore Coulomb</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s41">
                <title>Manfred Gessler</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s42">
                <title>Richard Dafydd Williams</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec id="s43">
                <title>Kathy Pritchard-Jones</title>
                <p>No relationship to disclose</p>
              </sec>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslow</surname><given-names>N</given-names></name><name><surname>Olshan</surname><given-names>A</given-names></name><name><surname>Beckwith</surname><given-names>JB</given-names></name>, etal</person-group>: <article-title>Epidemiology of Wilms tumor</article-title><source>Med Pediatr Oncol</source><volume>21</volume>:<fpage>172</fpage>–<lpage>181</lpage>,<year>1993</year><pub-id pub-id-type="pmid">7680412</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Moroz</surname><given-names>V</given-names></name><name><surname>Vujanic</surname><given-names>G</given-names></name>, etal</person-group>: <article-title>Treatment and outcome of Wilms’ tumour patients: An analysis of all cases registered in the UKW3 trial</article-title><source>Ann Oncol</source><volume>23</volume>:<fpage>2457</fpage>–<lpage>2463</lpage>,<year>2012</year><pub-id pub-id-type="pmid">22415585</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalapurakal</surname><given-names>JA</given-names></name><name><surname>Dome</surname><given-names>JS</given-names></name><name><surname>Perlman</surname><given-names>EJ</given-names></name>, etal</person-group>: <article-title>Management of Wilms’ tumour: Current practice and future goals</article-title><source>Lancet Oncol</source><volume>5</volume>:<fpage>37</fpage>–<lpage>46</lpage>,<year>2004</year><pub-id pub-id-type="pmid">14700607</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vujanić</surname><given-names>GM</given-names></name><name><surname>Sandstedt</surname><given-names>B</given-names></name><name><surname>Harms</surname><given-names>D</given-names></name>, etal</person-group>: <article-title>Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood</article-title><source>Med Pediatr Oncol</source><volume>38</volume>:<fpage>79</fpage>–<lpage>82</lpage>,<year>2002</year><pub-id pub-id-type="pmid">11813170</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Bergeron</surname><given-names>C</given-names></name><name><surname>de Camargo</surname><given-names>B</given-names></name>, etal</person-group>: <article-title>Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial</article-title><source>Lancet</source><volume>386</volume>:<fpage>1156</fpage>–<lpage>1164</lpage>,<year>2015</year><pub-id pub-id-type="pmid">26164096</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Bergeron</surname><given-names>C</given-names></name>, etal</person-group>: <article-title>Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)</article-title><source>Eur J Cancer</source><volume>51</volume>:<fpage>498</fpage>–<lpage>506</lpage>,<year>2015</year><pub-id pub-id-type="pmid">25592561</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetta</surname><given-names>L</given-names></name><name><surname>Kuehn</surname><given-names>SE</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name>, etal</person-group>: <article-title>Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts</article-title><source>Science</source><volume>250</volume>:<fpage>994</fpage>–<lpage>997</lpage>,<year>1990</year><pub-id pub-id-type="pmid">2173146</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Call</surname><given-names>KM</given-names></name><name><surname>Glaser</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>CY</given-names></name>, etal</person-group>: <article-title>Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus</article-title><source>Cell</source><volume>60</volume>:<fpage>509</fpage>–<lpage>520</lpage>,<year>1990</year><pub-id pub-id-type="pmid">2154335</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gessler</surname><given-names>M</given-names></name><name><surname>Poustka</surname><given-names>A</given-names></name><name><surname>Cavenee</surname><given-names>W</given-names></name>, etal</person-group>: <article-title>Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping</article-title><source>Nature</source><volume>343</volume>:<fpage>774</fpage>–<lpage>778</lpage>,<year>1990</year><pub-id pub-id-type="pmid">2154702</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koesters</surname><given-names>R</given-names></name><name><surname>Ridder</surname><given-names>R</given-names></name><name><surname>Kopp-Schneider</surname><given-names>A</given-names></name>, etal</person-group>: <article-title>Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors</article-title><source>Cancer Res</source><volume>59</volume>:<fpage>3880</fpage>–<lpage>3882</lpage>,<year>1999</year><pub-id pub-id-type="pmid">10463574</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>MN</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Wells</surname><given-names>J</given-names></name>, etal</person-group>: <article-title>An X chromosome gene, WTX, is commonly inactivated in Wilms tumor</article-title><source>Science</source><volume>315</volume>:<fpage>642</fpage>–<lpage>645</lpage>,<year>2007</year><pub-id pub-id-type="pmid">17204608</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Falkoff</surname><given-names>D</given-names></name><name><surname>Petruzzi</surname><given-names>MJ</given-names></name>, etal</person-group>: <article-title>Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations</article-title><source>Nat Genet</source><volume>7</volume>:<fpage>91</fpage>–<lpage>97</lpage>,<year>1994</year><pub-id pub-id-type="pmid">8075648</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RD</given-names></name><name><surname>Al-Saadi</surname><given-names>R</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name>, etal</person-group>: <article-title>Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor</article-title><source>Clin Cancer Res</source><volume>16</volume>:<fpage>2036</fpage>–<lpage>2045</lpage>,<year>2010</year><pub-id pub-id-type="pmid">20332316</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakheja</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>KS</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name>, etal</person-group>: <article-title>Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours</article-title><source>Nat Commun</source><volume>2</volume>:<fpage>4802</fpage>,<year>2014</year><pub-id pub-id-type="pmid">25190313</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrezan</surname><given-names>GT</given-names></name><name><surname>Ferreira</surname><given-names>EN</given-names></name><name><surname>Nakahata</surname><given-names>AM</given-names></name>, etal</person-group>: <article-title>Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour</article-title><source>Nat Commun</source><volume>5</volume>:<fpage>4039</fpage>,<year>2014</year><pub-id pub-id-type="pmid">24909261</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <comment>Walz AL, Ooms A, Gadd S, et al: Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286-297, 2015[Erratum: Cancer Cell 27:426, 2015]</comment>
                </mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wegert</surname><given-names>J</given-names></name><name><surname>Ishaque</surname><given-names>N</given-names></name><name><surname>Vardapour</surname><given-names>R</given-names></name>, etal</person-group>: <article-title>Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors</article-title><source>Cancer Cell</source><volume>27</volume>:<fpage>298</fpage>–<lpage>311</lpage>,<year>2015</year><pub-id pub-id-type="pmid">25670083</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RD</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name><name><surname>Alcaide-German</surname><given-names>M</given-names></name>, etal</person-group>: <article-title>Multiple mechanisms of MYCN dysregulation in Wilms tumour</article-title><source>Oncotarget</source><volume>6</volume>:<fpage>7232</fpage>–<lpage>7243</lpage>,<year>2015</year><pub-id pub-id-type="pmid">25749049</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RH</given-names></name><name><surname>Douglas</surname><given-names>J</given-names></name><name><surname>Baskcomb</surname><given-names>L</given-names></name>, etal</person-group>: <article-title>Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor</article-title><source>Nat Genet</source><volume>40</volume>:<fpage>1329</fpage>–<lpage>1334</lpage>,<year>2008</year><pub-id pub-id-type="pmid">18836444</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>PE</given-names></name><name><surname>Breslow</surname><given-names>NE</given-names></name><name><surname>Li</surname><given-names>S</given-names></name>, etal</person-group>: <article-title>Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group</article-title><source>J Clin Oncol</source><volume>23</volume>:<fpage>7312</fpage>–<lpage>7321</lpage>,<year>2005</year><pub-id pub-id-type="pmid">16129848</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maschietto</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>RD</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name>, etal</person-group>: <article-title>TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia</article-title><source>PLoS One</source><volume>9</volume>:<fpage>e109924</fpage>,<year>2014</year><pub-id pub-id-type="pmid">25313908</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hing</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>YJ</given-names></name><name><surname>Summersgill</surname><given-names>B</given-names></name>, etal</person-group>: <article-title>Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors</article-title><source>Am J Pathol</source><volume>158</volume>:<fpage>393</fpage>–<lpage>398</lpage>,<year>2001</year><pub-id pub-id-type="pmid">11159177</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YJ</given-names></name><name><surname>Hing</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name>, etal</person-group>: <article-title>Chromosome 1q expression profiling and relapse in Wilms’ tumour</article-title><source>Lancet</source><volume>360</volume>:<fpage>385</fpage>–<lpage>386</lpage>,<year>2002</year><pub-id pub-id-type="pmid">12241781</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natrajan</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>RD</given-names></name><name><surname>Hing</surname><given-names>SN</given-names></name>, etal</person-group>: <article-title>Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse</article-title><source>J Pathol</source><volume>210</volume>:<fpage>49</fpage>–<lpage>58</lpage>,<year>2006</year><pub-id pub-id-type="pmid">16823893</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perotti</surname><given-names>D</given-names></name><name><surname>Spreafico</surname><given-names>F</given-names></name><name><surname>Torri</surname><given-names>F</given-names></name>, etal</person-group>: <article-title>Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse</article-title><source>Genes Chromosomes Cancer</source><volume>51</volume>:<fpage>644</fpage>–<lpage>653</lpage>,<year>2012</year><pub-id pub-id-type="pmid">22407497</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratias</surname><given-names>EJ</given-names></name><name><surname>Jennings</surname><given-names>LJ</given-names></name><name><surname>Anderson</surname><given-names>JR</given-names></name>, etal</person-group>: <article-title>Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children’s Oncology Group</article-title><source>Cancer</source><volume>119</volume>:<fpage>3887</fpage>–<lpage>3894</lpage>,<year>2013</year><pub-id pub-id-type="pmid">23983061</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segers</surname><given-names>H</given-names></name><name><surname>van den Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>Williams</surname><given-names>RD</given-names></name>, etal</person-group>: <article-title>Gain of 1q is a marker of poor prognosis in Wilms’ tumors</article-title><source>Genes Chromosomes Cancer</source><volume>52</volume>:<fpage>1065</fpage>–<lpage>1074</lpage>,<year>2013</year><pub-id pub-id-type="pmid">24038759</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>JP</given-names></name><name><surname>McElgunn</surname><given-names>CJ</given-names></name><name><surname>Waaijer</surname><given-names>R</given-names></name>, etal</person-group>: <article-title>Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification</article-title><source>Nucleic Acids Res</source><volume>30</volume>:<fpage>e57</fpage>,<year>2002</year><pub-id pub-id-type="pmid">12060695</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="book">
                  <comment>Furtwängler R, Pritchard-Jones K: Treatment of Wilms tumour: The SIOP approach, in Pritchard-Jones K, Dome JS (eds): Renal Tumours of Childhood: Biology and Therapy. Berlin Heidelberg, Germany, Springer-Verlag, 2014, pp 101-118</comment>
                </mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RD</given-names></name><name><surname>Al-Saadi</surname><given-names>R</given-names></name><name><surname>Natrajan</surname><given-names>R</given-names></name>, etal</person-group>: <article-title>Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor</article-title><source>Genes Chromosomes Cancer</source><volume>50</volume>:<fpage>982</fpage>–<lpage>995</lpage>,<year>2011</year><pub-id pub-id-type="pmid">21882282</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>DA</given-names></name><name><surname>Shear</surname><given-names>TD</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name>, etal</person-group>: <article-title>Clinical and biologic significance of nuclear unrest in Wilms tumor</article-title><source>Cancer</source><volume>97</volume>:<fpage>2318</fpage>–<lpage>2326</lpage>,<year>2003</year><pub-id pub-id-type="pmid">12712489</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>N</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name>, etal</person-group>: <article-title>Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis?</article-title><source>Pediatr Blood Cancer</source><volume>57</volume>:<fpage>741</fpage>–<lpage>742</lpage>,<year>2011</year></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
